|
Oct. 23, 2025
| This week’s gene therapy news and insights for biopharma leaders
A shot analysts projected as a multibillion-dollar seller produced results “well below” the company’s expectations, heightening pressure on Moderna’s flagging respiratory vaccine business.
|
The plans, if implemented, would result in the layoff of about 365 employees. Galapagos said it will still entertain acquisition offers as it works to close the unit.
|
A gene therapy from Regeneron, a pancreatic cancer medicine from Revolution Medicines and a porphyria drug from Disc Medicine were among the first beneficiaries of a pilot program initiated in June.
|
Patent protection will expire soon for many blockbuster drugs, pushing pharma giants to seek new products and markets. Explore key market trends shaping the commercialization strategies of major drugmakers in
|
News roundup
I-Mab is rebranding as a company that will form individual drugmaking subsidiaries. Elsewhere, Sanofi cut an immune drug deal and investors poured $140 million into a new hair loss treatment.
|
What We're Reading
Science
|
The Financial Times
|
Stat
|
Upcoming Events
| 
